Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Donken, RHoes, J
Knol, MJ
Ogilvie, GS
Dobson, S
King, AJ
Singer, J
Woestenberg, PJ
Bogaards, JA
Meijer, CJLM
de Melker, HE
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approachesPublished in
BMC Infect Dis 2020; 20(1):482PMID
32640998ae974a485f413a2113503eed53cd6c53
10.1186/s12879-020-05083-7
Scopus Count
Collections
Related articles
- High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
- Authors: Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE
- Issue date: 2018 Apr 23
- Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
- Authors: Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG
- Issue date: 2016 May 24
- Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
- Authors: Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA
- Issue date: 2013 Jul
- Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
- Authors: Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T
- Issue date: 2019 Jan 9
- Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
- Authors: Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group
- Issue date: 2015 Apr